Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares his excitement for upcoming presentations in the myeloproliferative neoplasms field at ASH 2020. There will be a continued focus on novel targets such as telomerase and bromodomains, as well as late-breaking discoveries surrounding the common JAK2 V617F mutation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.